Clinical Trials

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT03601923 2026-03-25

Niraparib in Patients With Pancreatic Cancer

32 enrolled

Pancreatic Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

11 enrolled 13 charts

Prostate Adenocarcinoma

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT05442749 2026-02-17

PARPi-PANC

2 enrolled

Pancreatic Neoplasms

NCT04068753 2026-02-10

STAR

66 enrolled

Uterine Cervical Neoplasms

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

120 enrolled

Brain Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

20 enrolled

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

30 enrolled

Glioblastoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT03983993 2026-01-05

NIPAVect

26 enrolled 8 charts

Colorectal Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

Prostatic Neoplasms

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled

Penile Neoplasms

NCT04779151 2025-12-01

NIRADO

GastrointestinalGenitourinaryHead & Neck

51 enrolled

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT06180356 2025-11-28

ANALLISA

30 enrolled

Ovarian Neoplasms

NCT05515575 2025-10-20

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

8 enrolled

Sarcoma

NCT04837209 2025-10-01

NADiR

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06527690 2025-09-29

REPRESENTATION

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06747845 2025-09-16

ParpVax2

68 enrolled

Pancreatic Adenocarcinoma Metastatic

NCT04030559 2025-08-26

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

11 enrolled

Prostatic Neoplasms

NCT04080284 2025-08-19

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

22 enrolled

Uterine Neoplasms, Endometrial Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

18 enrolled 11 charts

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

22 enrolled 17 charts

Pancreatic Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

62 enrolled

Breast

Breast Neoplasms

NCT04341181 2025-07-25

ProTarget

300 enrolled

Tumor-Agnostic

Neoplasms

NCT03783949 2025-06-11

EUDARIO

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05297864 2025-05-23

OU-SCC-PI-4G

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT05455424 2025-05-15

NERO

Other solid neoplasmThoracic

88 enrolled

Mesothelioma, Malignant, Mesothelioma, Recurrence

NCT06212583 2025-05-01

KNIGHTS

88 enrolled

Prostatic Neoplasms

NCT05990192 2025-04-22

SOPRANO

42 enrolled

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

GastrointestinalOther solid neoplasm

770 enrolled

Rare Tumor

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

MMR-D/MSI-H Colorectal Cancers

NCT03891576 2025-01-17

Newton

Classical hematologyGynecologic

83 enrolled

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

67 enrolled

Ovarian Neoplasms

NCT04812366 2024-12-16

GUNS

315 enrolled

Prostatic Neoplasms

NCT04185831 2024-08-22

MEGALiT

167 enrolled

Other solid neoplasm

Solid Tumor

NCT04313504 2024-08-01

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

23 enrolled

Head & Neck

Head and Neck Neoplasms

NCT03840967 2024-06-04

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

14 enrolled 11 charts

Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04240106 2024-02-16

LUZERN

Phase 2 Not yet recruiting

14 enrolled

Breast

Breast Neoplasms

NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

33 enrolled

Efficacy

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2 Unknown

51 enrolled

Endometrial Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

83 enrolled

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT04284852 2023-12-15

NEOPRIMA

20 enrolled